US 12,435,117 B2
Method for producing immune cells and use thereof
Yee Sook Cho, Daejeon (KR); Han-Seop Kim, Daejeon (KR); Jae Yun Kim, Daejeon (KR); and Binna Seol, Daejeon (KR)
Assigned to KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR)
Appl. No. 17/598,917
Filed by KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR)
PCT Filed Mar. 27, 2020, PCT No. PCT/KR2020/004198
§ 371(c)(1), (2) Date Sep. 28, 2021,
PCT Pub. No. WO2020/197319, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 10-2019-0036264 (KR), filed on Mar. 28, 2019; and application No. 10-2019-0036265 (KR), filed on Mar. 28, 2019.
Prior Publication US 2022/0160769 A1, May 26, 2022
Int. Cl. A61K 35/17 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/435 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4205 (2025.01); A61K 40/4211 (2025.01); A61K 40/4255 (2025.01); A61P 35/00 (2018.01); C07K 14/43504 (2013.01); C07K 14/4748 (2013.01); C07K 14/70503 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C12N 5/0646 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2239/28 (2023.05); A61K 2239/38 (2023.05); A61K 2239/54 (2023.05); C12N 2501/125 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2318 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/26 (2013.01); C12N 2501/60 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/727 (2013.01)] 12 Claims
 
1. A method for producing iNKT (induced natural killer T) cells, comprising: culturing isolated cells introduced with I) a reprogramming factor or II) a reprogramming factor and a CAR (chimeric antigen receptor) gene sequentially in a) a first medium containing SCF (Stem Cell Factor), FLT3L(FMS-related Tyrosine Kinase-3 Ligand), IL(Interleukin)-3, IL-6, and CHIR99021; and b) a second medium containing (1) SCF, FLT3L, IL-2, IL-7, IL-15, FICZ and biochanin A, or (2) SCF, FLT3L, IL-2, IL-7, IL-15, and UCHT1, and thereby directly reprogramming into NKT cells without passing through pluripotent stem cells.